| Date Filed | Type | Description |
| 03/16/2018 |
GN
| TearLab Corporation Announces Voluntary Delisting From Toronto Stock Exchange |
| 03/02/2018 |
GN
| TearLab Corporation Reports Fourth Quarter and Full Year 2017 Financial Results |
| 02/28/2018 |
GN
| TearLab Osmolarity System Launches in Brazil |
| 02/14/2018 |
GN
| TearLab Provides Updates on Its Osmolarity Test and TearLab Discovery™ Platform |
| 01/04/2018 |
GN
| TearLab Submits 510(k) for U.S. FDA Clearance of TearLab Discovery™ Platform |
| 12/06/2017 |
GN
| TearLab Prices $3.0 Million Registered Direct Offering |
| 11/30/2017 |
GN
| TearLab Launches Registered Direct Offering |
| 11/13/2017 |
GN
| TearLab Corporation Reports Third Quarter and September Year-To-Date 2017 Financial Results |
| 11/09/2017 |
GN
| TearLab Corporation Begins Trading on OTCQB |
| 11/01/2017 |
GN
| TearLab Corporation to Release Third Quarter 2017 Financial Results on November 13, 2017 |
| 10/17/2017 |
GN
| TearLab Corporation Provides Update on U.S. Regulatory Strategy for TearLab Discovery™ System |
| 09/27/2017 |
GN
| TearLab Corporation Announces Release of 2018 - 2020 Preliminary Reimbursement Rates |
| 08/30/2017 |
GN
| TearLab Receives Nasdaq Listing Extension |
| 08/14/2017 |
GN
| TearLab Corporation Reports Second Quarter and First Half 2017 Financial Results |
| 07/21/2017 |
GN
| TearLab Announces European Regulatory Clearance for Next-Generation TearLab Discovery™ System |
| 06/21/2017 |
GN
| TearLab Receives Nasdaq Listing Extension |
| 05/15/2017 |
GN
| TearLab Corporation Reports First Quarter 2017 Financial Results |
| 05/12/2017 |
GN
| TearLab Osmolarity System Receives Brazilian Regulatory Approval |
| 05/12/2017 |
GN
| TearLab Osmolarity System Receives Brazilian Regulatory Approval |
| 05/01/2017 |
GN
| TearLab Corporation to Release First Quarter 2017 Financial Results on May 15, 2017 |
| 03/06/2017 |
GN
| TearLab Announces CE Marking for Next-Generation System |
| 03/06/2017 |
GN
| TearLab Announces CE Marking for Next-Generation System |
| 02/24/2017 |
GN
| TearLab Announces 1-for-10 Reverse Split of Common Stock |
| 02/24/2017 |
GN
| TearLab Announces 1-for-10 Reverse Split of Common Stock |
| 02/21/2017 |
GN
| TearLab Corporation to Report Fourth Quarter and Full-year 2016 Financial Results on March 9, 2017 |
| 02/13/2017 |
GN
| TearLab Provides Update on International Market Milestones |
| 02/13/2017 |
GN
| TearLab Provides Update on International Market Milestones |
| 08/20/2012 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)] |
| 08/14/2012 |
EFFECT
| Form EFFECT - Notice of Effectiveness |
| 08/14/2012 |
EFFECT
| Form EFFECT - Notice of Effectiveness |
| 08/07/2012 |
4
| SULLIVAN TRUDY F (President & CEO) has filed a Form 4 on TALBOTS INC|
Txns:
| Unknown transaction of 507,400 shares
@ $2.75, valued at
$1.4M
Disposed/sold 187,100 options to buy
@ $2.36, valued at
$441.6k
|
|
| 08/07/2012 |
4
| SCARPA MICHAEL (COO, CFO and Treasurer) has filed a Form 4 on TALBOTS INC|
Txns:
| Disposed/sold 75,000 options to buy
@ $2, valued at
$150k
Disposed/sold 131,250 options to buy
@ $2.36, valued at
$309.8k
|
|
| 08/07/2012 |
4
| CASAMENTO BENEDETTA I (EVP, Finance) has filed a Form 4 on TALBOTS INC|
Txns:
| Disposed/sold 85,226 shares
@ $2.75, valued at
$234.4k
|
|
| 08/07/2012 |
4
| FITZGERALD DEIRDRE (EVP, Gen Merchandise Manager) has filed a Form 4 on TALBOTS INC|
Txns:
| Unknown transaction of 16,699 shares
@ $2.75, valued at
$45.9k
Disposed/sold 8,500 options to buy
@ $2.36, valued at
$20.1k
|
|
|